Essex Woodlands is a healthcare growth equity and venture capital firm.
Business Model:
Revenue: $10M
Employees: 11-50
Address: 21 Waterway Avenue
City: The Woodlands
State: TX
Zip: 77380
Country: US
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world&s;s largest and most established healthcare venture capital firms. The team is comprised of 23 professionals with principal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience. For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.
Contact Phone:
+12813641555
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2007 | Revance Therapeutics | Series C | 0 |
1/2004 | BioForm Medical | Venture Round | - |
12/2006 | NeoVista | Series C | 41M |
12/2005 | Light Sciences Oncology | Series A | 32M |
1/2001 | Cord Blood Registry | Venture Round | - |
10/2009 | Qspex Technologies | Venture Round | 12M |
1/2006 | Symphogen | Series D | 0 |
6/2019 | Tissuetech | Series C | 82.3M |
1/2008 | Oraya Therapeutics | Series B | 18M |
6/2007 | Oraya Therapeutics | Series A | 4M |
9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
7/2007 | Xanodyne | Series A | 25M |
1/2008 | ATS Medical | Funding Round | - |
10/2010 | ProteinSimple | Series F | 20M |
1/2007 | MicroPort Scientific | Private Equity Round | - |
3/2009 | Victory Pharma | Venture Round | 10M |
12/2011 | Grupo Biotoscana SL | Private Equity Round | - |
3/2000 | Healthgrades | Post-IPO Equity | 18M |
1/2000 | WholePeople.com | Venture Round | 35M |
7/2015 | Qspex Technologies | Debt Financing | 0 |
9/2015 | Kona Medical | Debt Financing | 10M |
12/2012 | Kona Medical | Series C | 10M |
12/2009 | Revance Therapeutics | Series D | 0 |
8/2000 | Control Delivery Systems | Venture Round | 0 |
6/2004 | Xanodyne | Venture Round | 20M |
4/2004 | Revance Therapeutics | Series B | 13M |
4/2013 | Revance Therapeutics | Series E | 33M |
2/2009 | Symphogen | Venture Round | 42.3M |
1/2006 | Touchstone Health | Private Equity Round | - |
5/2007 | StrataGent Life Sciences | Series B | 0 |
9/2010 | Accumetrics | Venture Round | 0 |
4/2006 | Chroma Therapeutics | Series C | 53M |
5/2012 | NeoVista | Venture Round | 6M |
9/2007 | Corium International | Series C | 40M |
1/2003 | Iomai Corporation | Series C | 54M |
10/2009 | Accumetrics | Series E | 0 |
6/2002 | Confluent Surgical | Series C | 20M |
3/2004 | InSound Medical | Series D | 17.2M |
8/2011 | Entellus Medical | Series E | 0 |
3/2005 | Confluent Surgical | Series D | 0 |
3/2008 | Nellix | Series C | 0 |
6/2009 | Chroma Therapeutics | Series D | 0 |
10/2009 | Xanodyne | Venture Round | 0 |
1/2005 | Bausch Health | Venture Round | - |
6/2016 | Suneva Medical | Series D | 25M |
1/2005 | Dow Pharmaceutical Sciences | Venture Round | - |
1/2002 | Symphogen | Series B | 0 |
8/2010 | Complete Genomics | Series E | 39M |
12/2011 | IntegenX | Series C | 40M |
11/2004 | Symphogen | Series C | 0 |
1/2007 | Healthcare Brands International Ltd | Venture Round | - |
7/2020 | Cardiva Medical | Venture Round | 0 |
7/2004 | LipoSonix | Series C | 27M |
2/2002 | Inhibitex | Venture Round | 20M |
1/2001 | Rinat Neuroscience | Series A | 17.5M |
8/2001 | Spinal Concepts | Series E | 21M |
10/2002 | MicroMed Technology | Series D | 23M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
6/2007 | Millennium Pharmacy Systems | Venture Round | 40M |
5/2010 | TearScience | Series C | 44.5M |
1/2011 | Symphogen | Venture Round | 0 |
8/2009 | Complete Genomics | Series D | 45M |
6/2000 | iKnowMed | Series C | 30.7M |
1/2013 | Yantai Beacon Medical | Private Equity Round | - |
2/2017 | Xenex | Venture Round | 0 |
7/2009 | Oraya Therapeutics | Series C | 42M |
6/2011 | Revance Therapeutics | Series D | 45M |
5/2012 | Kona Medical | Series C | 0 |
7/2007 | Horizon Pharma | Series C | 30M |
2/2008 | Accumetrics | Series D | 0 |
10/2010 | Endologix | Post-IPO Equity | 15M |
7/2003 | InSound Medical | Series D | 6.5M |
11/2009 | Entellus Medical | Series D | 30M |
6/2001 | InSound Medical | Venture Round | 7M |
1/2007 | Global Cord Blood Corporation | Private Equity Round | - |
9/2006 | Prism Pharmaceuticals | Series B | 15M |
7/2007 | Orthovita | Post-IPO Equity | 32.5M |
8/2015 | AxoGen | Post-IPO Equity | 0 |
4/2016 | TearScience | Series D | 0 |
10/2005 | Light Sciences Oncology | Series A | 35M |
4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
6/2012 | Qspex Technologies | Series D | 0 |
1/2010 | Velcera | Venture Round | - |
12/2016 | Prolacta Bioscience | Venture Round | 0 |
8/2016 | Metabolon | Venture Round | 0 |
3/2009 | NeoVista | Series D | 18M |
2/2007 | Alaunos Therapeutics | Post-IPO Equity | 0 |
12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
4/2005 | Receptor Biologix | Series A | 33.6M |
8/2003 | Rinat Neuroscience | Series B | 40M |
1/2007 | Ception Therapeutics | Series C | 63M |
1/2003 | LifeCell | Private Equity Round | - |
2/2011 | NeoVista | Series E | 33M |
12/2009 | Molecular Partners | Series B | 44.2M |
7/2004 | Accumetrics | Series B | 0 |
9/2011 | BreatheAmerica | Series B | 22M |
5/2012 | Bioventus | Venture Round | 0 |
1/2010 | ikaSystems | Private Equity Round | 120M |
11/2012 | BreatheAmerica | Venture Round | 5M |
3/2007 | EUSA Pharma | Venture Round | - |
7/2020 | Cardiva Medical | Venture Round | 0 |
6/2019 | Tissuetech | Series C | 0 |
2/2017 | Xenex | Venture Round | 0 |
12/2016 | Prolacta Bioscience | Venture Round | 0 |
8/2016 | Metabolon | Venture Round | 0 |
6/2016 | Suneva Medical | Series D | 0 |
4/2016 | TearScience | Series D | 0 |
9/2015 | Kona Medical | Debt Financing | 0 |
8/2015 | AxoGen | Post-IPO Equity | 0 |
7/2015 | Qspex Technologies | Debt Financing | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|